Literature DB >> 22423910

Re: Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Patrick C Walsh.   

Abstract

Entities:  

Year:  2012        PMID： 22423910     DOI： 10.1016/j.juro.2012.01.012

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  7 in total

1.  PSA testing still essential.

Authors:  Tony Finelli
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

2.  La mesure de l'APS demeure essentielle.

Authors:  François Bénard
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

Review 3.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

4.  Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Authors:  Laurence Klotz; Michael Chetner; Joseph Chin; Tony Finelli; Neil Fleshner; Yves Fradet; Larry Goldenberg; J Curtis Nickel; Robert Siemens; Alan So; Linda Sugar; Alexandre Zlotta; Eric Klein; Howard Parnes; David Penson
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

Review 5.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

6.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  F1000 Med Rep       Date:  2012-08-01

Review 7.  Management of low risk prostate cancer-active surveillance and focal therapy.

Authors:  Laurence Klotz; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-05-13       Impact factor: 66.675
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.